Indivumed, GmbH and Regeneron Pharmaceuticals Inc. signed an agreement providing Regeneron with access to Indivumed’s quality tissue sample and clinical and molecular data collection methods, to support the company’s cancer research programs.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
